Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBT Margin (2020 - 2025)

Historic EBT Margin for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to 6.33%.

  • GeneDx Holdings' EBT Margin rose 45500.0% to 6.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.62%, marking a year-over-year increase of 321400.0%. This contributed to the annual value of 17.23% for FY2024, which is 700000.0% up from last year.
  • Latest data reveals that GeneDx Holdings reported EBT Margin of 6.33% as of Q3 2025, which was up 45500.0% from 10.29% recorded in Q2 2025.
  • GeneDx Holdings' 5-year EBT Margin high stood at 75.8% for Q3 2021, and its period low was 503.13% during Q4 2022.
  • Over the past 5 years, GeneDx Holdings' median EBT Margin value was 69.52% (recorded in 2021), while the average stood at 102.53%.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -4336100bps in 2022, then surged by 4575300bps in 2023.
  • GeneDx Holdings' EBT Margin (Quarter) stood at 69.52% in 2021, then tumbled by -624bps to 503.13% in 2022, then soared by 91bps to 45.6% in 2023, then soared by 112bps to 5.66% in 2024, then tumbled by -212bps to 6.33% in 2025.
  • Its last three reported values are 6.33% in Q3 2025, 10.29% for Q2 2025, and 6.98% during Q1 2025.